KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 5,104 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 5,104 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the transaction, the chief executive officer now owns 278,855 shares in the company, valued at $2,738,356.10. The trade was a 1.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

KalVista Pharmaceuticals Stock Up 9.5 %

Shares of KalVista Pharmaceuticals stock traded up $0.93 during trading hours on Wednesday, hitting $10.71. 515,932 shares of the company’s stock traded hands, compared to its average volume of 304,464. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The stock has a 50 day simple moving average of $8.80 and a 200-day simple moving average of $10.43. The company has a market cap of $529.29 million, a PE ratio of -2.94 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.01. As a group, equities research analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in KALV. Vestal Point Capital LP grew its holdings in KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after acquiring an additional 1,700,000 shares in the last quarter. Boxer Capital Management LLC acquired a new position in KalVista Pharmaceuticals in the fourth quarter worth about $13,467,000. Octagon Capital Advisors LP bought a new stake in KalVista Pharmaceuticals in the fourth quarter valued at about $11,604,000. Frazier Life Sciences Management L.P. raised its stake in KalVista Pharmaceuticals by 32.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock valued at $41,400,000 after buying an additional 1,200,000 shares in the last quarter. Finally, Stempoint Capital LP acquired a new stake in KalVista Pharmaceuticals during the fourth quarter valued at approximately $8,409,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on KALV shares. Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price objective for the company. JMP Securities initiated coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Finally, TD Cowen initiated coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).